Figure 6From: Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? Time to progression by irRC simulating RECIST1.1 was much longer compared to that by conventional RECIST1.1 with median TTP of 3.7 mos (95% CI: 2.7-5.3). Back to article page